{
  "@context": "https://schema.org/",
  "@type": "MedicalCondition",
  "@id": "aku:vascular:thrombophilia:protein-c-deficiency",
  "name": "Protein C Deficiency",
  "alternateName": ["PC Deficiency", "Hereditary Protein C Deficiency"],
  "description": "Inherited or acquired deficiency of protein C, a vitamin K-dependent anticoagulant that inactivates factors Va and VIIIa. Major risk factor for venous thromboembolism with distinctive association with warfarin-induced skin necrosis.",
  "code": [
    {
      "@type": "MedicalCode",
      "codeValue": "D68.59",
      "codingSystem": "ICD-10-CM"
    },
    {
      "@type": "MedicalCode",
      "codeValue": "76407009",
      "codingSystem": "SNOMED-CT",
      "name": "Protein C deficiency"
    }
  ],
  "classification": {
    "domain_path": "health-sciences/medicine/surgery/vascular/pathology/dvt/thrombophilia",
    "type": "definition",
    "subtype": "inherited_thrombophilia",
    "difficulty": "advanced",
    "board_yield": "HIGH"
  },
  "pathophysiology": {
    "mechanism": "Protein C is activated by thrombin-thrombomodulin complex on endothelial surfaces. Activated protein C (APC), with cofactor protein S, proteolytically inactivates factors Va and VIIIa, limiting thrombin generation",
    "inheritance": "Autosomal dominant with variable penetrance",
    "gene": "PROC gene on chromosome 2q14.3",
    "types": [
      {
        "type": "Type I",
        "description": "Quantitative deficiency - reduced antigen and activity levels",
        "frequency": "More common"
      },
      {
        "type": "Type II", 
        "description": "Qualitative deficiency - normal antigen, reduced activity",
        "frequency": "Less common"
      }
    ],
    "prevalence": "0.2-0.4% in general population, 3-5% of VTE patients"
  },
  "clinical_features": {
    "vte_risk": {
      "heterozygous": "7-10 fold increased risk",
      "homozygous": "Severe, often fatal neonatal purpura fulminans"
    },
    "manifestations": [
      "Deep vein thrombosis",
      "Pulmonary embolism",
      "Superficial thrombophlebitis",
      "Mesenteric vein thrombosis",
      "Cerebral venous thrombosis"
    ],
    "warfarin_skin_necrosis": {
      "mechanism": "Protein C has shorter half-life (6-8 hours) than procoagulant factors. Early warfarin creates transient hypercoagulable state",
      "timing": "Days 3-6 of warfarin initiation",
      "location": "Fatty areas - breast, buttocks, thighs",
      "prevention": "Bridge with heparin, low-dose warfarin initiation"
    },
    "neonatal_purpura_fulminans": {
      "description": "Homozygous or compound heterozygous state",
      "presentation": "DIC, widespread skin necrosis within hours of birth",
      "treatment": "Fresh frozen plasma, protein C concentrate"
    }
  },
  "diagnosis": {
    "laboratory": {
      "screening": "Protein C activity assay (functional)",
      "confirmatory": "Protein C antigen level (immunologic)",
      "interpretation": {
        "normal_range": "70-140% activity",
        "deficiency": "<70% activity on two separate occasions"
      }
    },
    "timing_considerations": [
      "Do not test during acute VTE (consumption)",
      "Do not test during warfarin therapy (vitamin K-dependent)",
      "Wait 2-4 weeks after stopping warfarin",
      "Liver disease causes acquired deficiency"
    ],
    "differential": [
      "Vitamin K deficiency",
      "Liver disease",
      "DIC",
      "Warfarin therapy"
    ]
  },
  "management": {
    "acute_vte": {
      "treatment": "Standard anticoagulation (heparin, then warfarin or DOAC)",
      "warfarin_bridging": "Mandatory - continue heparin until INR therapeutic for 2+ days"
    },
    "duration": {
      "first_vte_provoked": "3-6 months",
      "first_vte_unprovoked": "Consider indefinite",
      "recurrent_vte": "Indefinite anticoagulation"
    },
    "family_screening": "Recommended for first-degree relatives"
  },
  "clinical_pearls": [
    "Classic triad for warfarin skin necrosis: protein C deficiency + fatty tissue + early warfarin without bridging",
    "Half-life mnemonic: Protein C and S have Short half-lives (6-8 hours) vs Factor II (60-72 hours)",
    "Homozygous protein C deficiency presents at birth with purpura fulminans - fatal without replacement"
  ],
  "semantic_relations": {
    "broader": ["aku:vascular:thrombophilia:inherited"],
    "narrower": [],
    "related": [
      "aku:vascular:thrombophilia:protein-s-deficiency",
      "aku:vascular:dvt:warfarin-skin-necrosis",
      "aku:vascular:anticoagulation:warfarin"
    ]
  },
  "learning_objectives": [
    "Explain the mechanism of protein C in the anticoagulant pathway",
    "Describe the pathophysiology of warfarin-induced skin necrosis in protein C deficiency",
    "Outline appropriate diagnostic testing and timing considerations"
  ],
  "metadata": {
    "version": "1.0.0",
    "created": "2026-01-06T01:30:00.000Z",
    "updated": "2026-01-06T01:30:00.000Z",
    "contributors": ["copilot"],
    "status": "validated",
    "confidence": 0.95
  }
}
